Use of Mildronate in Geriatric Patients with Congestive Heart Failure

Aims: The aim of our investigation was to assess effectiveness of Mildronate in the treatment of aged patients with congestive heart failure. Methods: Ninety one patients with NYHA functioned class I to III heart failure were assessed. Study group consisted of 63 patients who got Mildronate 750 mg per day for one month together with conventional treatment. Control group which consisted of 28 patients got only conventional treatment. Objective and subjective state of study subjects were assessed, questionnaire on quality of life was completed, electrocardiogram was registered and 6 minute walking test was performed. Results: In the study group angina attacks decreased from 1.6 to 0.7 per day, and its intensity from 1.4 to 0.7 scores (in 7 score system), (p 0.05). Among the study group rales in lungs disappeared in 8 patients (12.6%), and in 3 patients (4.8%) oedema feet subsided. Systolic blood pressure decreased by 8 mmHg and diastolic by 4 mmHg. In control group these clinical changes during the period of study were not statistically significant. Conclusion: The study showed that mildronate was a safe and well tolerated medication in aged patient and helped to decrease the symptoms of heart failure, increased exercise tolerance and improved quality of life.

[1]  A. Phelan,et al.  The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase , 2003, Circulation research.

[2]  G. Lopaschuk,et al.  Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase , 2003, Circulation research.

[3]  E. Liepinsh,et al.  Mildronate: cardioprotective action through carnitine-lowering effect. , 2002, Trends in cardiovascular medicine.

[4]  G. Lopaschuk.  Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? , 2001, Coronary artery disease.

[5]  M. Hoshiai,et al.  MET-88 a γ-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction , 2000, Molecular and Cellular Biochemistry.

[6]  N. Matsuura,et al.  Effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on tissue carnitine and lipid levels in rats. , 2000, Biological & pharmaceutical bulletin.

[7]  E. Lewandowski.  Metabolic mechanisms associated with antianginal therapy. , 2000, Circulation research.

[8]  M. Decramer,et al.  Six minute walking distance in healthy elderly subjects. , 1999, The European respiratory journal.

[9]  J. Wilson,et al.  Circulatory status and response to cardiac rehabilitation in patients with heart failure. , 1996, Circulation.

[10]  J. Cleland,et al.  Assessment and diagnosis of heart failure , 1996, Journal of internal medicine.

[11]  B. Simkhovich,et al.  3-(2,2,2-Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. , 1988, Biochemical pharmacology.